Travel Medicine

2012 ◽  
pp. 495-515
Author(s):  
Abinash Virk
Keyword(s):  
Developing Countries ◽  
Deep Vein Thrombosis ◽  
Infectious Diseases ◽  
Travel Medicine ◽  
Developed Countries ◽  
The Political ◽  
Prevention Measures ◽  
Altitude Sickness ◽  
Vein Thrombosis ◽  
Deep Vein

Travel between developing countries and developed countries is increasing every year. Approximately 880 million passengers arrived at international airports in 2009. The increase in travel to Africa has outpaced the increase for all other regions by almost twice, with the rate of growth reaching 8.1% in 2006. Asian and Pacific Rim countries continue to hold substantial travel interest. Travel to the Middle East has kept pace with travel growth despite the political instability there. More people are traveling to destinations that present higher risks of infectious diseases. Knowledge of prevention measures for preventable diseases becomes increasingly important. Management of posttravel illness becomes increasingly important. Subjects covered include preparation for travel, deep vein thrombosis prevention, motion sickness, jet lag, altitude sickness, vaccination and immunization, and traveler's diarrhea.

scholarly journals PREVALENCE, DISTRIBUTION AND DETERMINANTS OF DEEP VEIN THROMBOSIS IN ADULT INDOOR STROKE POPULATION OF PESHAWAR DIVISION, PAKISTAN

2020 ◽  
Vol 18 (2) ◽  
pp. 59-67
Author(s):  
Muhammad Bilal ◽  
Imran Ullah ◽  
Syed Abdurehman Shah ◽  
Zahidullah Khan ◽  
Taj Muhammad Khan ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Public Health Problem ◽  
Developed Countries ◽  
Cross Sectional Study ◽  
Base Line ◽  
Cross Sectional ◽  
Vein Thrombosis ◽  
Stroke Population ◽  
Study Results ◽  
Deep Vein

Background: Stroke is a devastating public health problem worldwide, considered as the third leading cause of death in developed countries, and the leading cause of disability among adults. Deep vein thrombosis (DVT), including pulmonary embolism (PE) as a sequel, is a serious complication of various medical conditions including stroke. The purpose of this study was to determine frequency of deep vein thrombosis among patients presented with stroke. Materials and methods: This study was descriptive (cross-sectional) study, conducted in the Department of Neurology, Lady Reading Hospital, Peshawar over 6 months. In the study a total of 196 patients were observed. Base line investigations were done and ultrasound was carried out to diagnose deep vein thrombosis. All the laboratory investigations and ultrasound were done by single experience pathologist and sonologist having minimum of five years of experience respectively. Observation and examination was done by neurologist who was not aware about the study and data was recorded in a predesigned proforma. To control confounders and bias in the study results, strict exclusion criteria had been followed. Results: In this study mean age was 63 years with standard deviation ± 28.34. Forty two percent patients were male and 58% patients were female. More over 8% patients had deep vein thrombosis. Conclusion:Our study concludes that the frequency of deep vein thrombosis was 8% among patients presented with stroke.

Phlebitis, Pulmonary Emboli and Presidential Politics: Richard M. Nixon's Complicated Deep Vein Thrombosis

2013 ◽  
Vol 79 (2) ◽  
pp. 128-134 ◽  
Author(s):  
Luigi Pascarella ◽  
Theodore N. Pappas
Keyword(s):  
Health Care ◽  
Deep Vein Thrombosis ◽  
The United States ◽  
The Political ◽  
Pulmonary Emboli ◽  
Legal Proceedings ◽  
Vein Thrombosis ◽  
Richard Nixon ◽  
Recurrent Deep Vein Thrombosis ◽  
Deep Vein

In September of 1974, Richard Nixon resigned the Presidency of the United States during an impeachment investigation concerning the Watergate Affair. One month after his resignation, the former President had an exacerbation of his chronic deep vein thrombosis. He also received a Presidential pardon from Gerald Ford on the same day that his recurrent deep vein thrombosis was diagnosed. The political, legal, and medical events that unfolded in the fall of 1974 are the substance of this report. Presidents often receive medical care that stretches the ordinary as a result of their position and the importance of their actions. The events surrounding Richard Nixon's care for deep vein thrombosis and its complications were not unusual for Presidential health care but were closely intertwined with the legal proceedings during the prosecution of the Watergate defendants.

Prevention of Deep Vein Thrombosis In Patients In the United States with Infectious Diseases

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4389-4389
Author(s):  
Alpesh N Amin ◽  
Jay Lin ◽  
Daniel Wiederkehr
Keyword(s):  
At Risk ◽  
Deep Vein Thrombosis ◽  
Infectious Diseases ◽  
Research Funding ◽  
Total Duration ◽  
The United States ◽  
Post Discharge ◽  
Vein Thrombosis ◽  
Dvt Prophylaxis ◽  
Deep Vein

Abstract Abstract 4389 Background: Hospitalized patients with infectious diseases are at risk of venous thromboembolism (VTE), encompassing both deep-vein thrombosis (DVT) and pulmonary embolism (PE). Our analysis evaluated real-world thromboprophylaxis use and DVT/PE rates in patients with infectious diseases in hospital, and for 30 days post-discharge. Methods: Data were extracted from the US Premier Perspective(tm)-i3 Pharma Informatics linked database for patients with infectious disease (International Classification of Diseases Ninth Revision codes for infectious and parasitic diseases, skin infections, chronic infection, and postoperative infection) who had been admitted January 2005–November 2007. Included patients had at least 6 months’ continuous plan enrollment and were aged ≥ 18 years. Patients with a diagnosis of atrial fibrillation were excluded, as were patients with a hospital stay of 0 days or > 30 days. Results: Of the 5,488 at-risk patients analyzed, 31% received inpatient pharmacological or mechanical DVT prophylaxis, and 3.2% received outpatient pharmacological DVT prophylaxis. Mean ± standard deviation duration of prophylaxis was 1.1 ± 2.4 days for inpatients and 0.8 ± 4.6 days post-discharge, with a total duration of 1.9 ± 5.4 days. DVT/PE occurred in 3.61% of patients during hospitalization, and 0.98% of patients were rehospitalized or treated in the outpatient setting for DVT/PE. Conclusions: Our analysis highlights the considerable rate of DVT/PE and the underuse of DVT prophylaxis in hospitals. Furthermore, DVT/PE risk persisted post-discharge, yet few patients received outpatient prophylaxis. Improved prevention of DVT is required across the continuum of care to reduce preventable mortality and morbidity in patients with infectious diseases. Acknowledgment: this study was funded by sanofi-aventis U.S., Inc. The authors received editorial/writing support in the preparation of this abstract provided by Hester van Lier, PhD of Excerpta Medica, funded by sanofi-aventis U.S., Inc. Disclosures: Amin: sanofi-aventis US Inc.: Honoraria, Speakers Bureau. Lin:sanofi-aventis US Inc.: Employment, Research Funding. Wiederkehr:sanofi-aventis US Inc.: Research Funding.

Feasibility Study of Catheter-directed Thrombolysis with Recombinant Staphylokinase in Deep Venous Thrombosis

1998 ◽  
Vol 79 (03) ◽  
pp. 517-519 ◽  
Author(s):  
Stephane Heymans ◽  
Raymond Verhaeghe ◽  
Luc Stockx ◽  
Désiré Collen
Keyword(s):  
Deep Vein Thrombosis ◽  
Continuous Infusion ◽  
High Speed ◽  
Minor Bleeding ◽  
Vein Thrombosis ◽  
Catheter Directed Thrombolysis ◽  
Long Term Follow Up ◽  
Valve Function ◽  
Rotating Impeller ◽  
Deep Vein

SummaryThe feasibility of catheter-directed thrombolysis with recombinant staphylokinase was evaluated in six selected patients with deep vein thrombosis. The patients underwent intrathrombus infusion of recombinant staphylokinase (2 mg bolus followed by a continuous infusion of 1 mg/h). Heparin was given via the catheter as a bolus (5000 U) and as a continuous infusion (1000 U/h). Complete lyis was obtained in five patients and partial lysis in one patient. Complications consisted of minor bleeding in four subjects. Symptomatic reocclusion occurred in one. Debulking of the thrombus mass by a high speed rotating impeller (n = 1) and stenting (n = 3) were used as additional interventions. An underlying anatomical abnormality was present in two patients. Long term follow up revealed normal patency in all patients and normal valve function in four patients. Symptomatic venous insufficiency with valve dysfunction was present in the two with a second thrombotic episode.Thus catheter-directed infusion of recombinant staphylokinase in patients with deep vein thrombosis appears feasible and may be associated with a high frequency of thrombolysis. Larger studies to define the clinical benefit of this treatment appear to be warranted.

Deep Vein Thrombosis and Fibrinolysis

1991 ◽  
Vol 66 (04) ◽  
pp. 426-429 ◽  
Author(s):  
Marcel Levi ◽  
Anthonie W A Lensing ◽  
Harry R Büller ◽  
Paolo Prandoni ◽  
Gerard Dooijewaard ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Tissue Type ◽  
Controlled Study ◽  
First Episode ◽  
Control Group ◽  
Vein Thrombosis ◽  
Type Plasminogen Activator ◽  
Deep Vein

SummaryIn the present study 57 consecutive patients with a first episode of venographically proven deep vein thrombosis were investigated to evaluate the release of tissue-type plasminogen activator (t-PA) and of urokinase-type plasminogen activator (u-PA) in response to DDAVP stimulation as well as the resting plasminogen activator inhibitor (PAI) concentration, comparing this to the results obtained in 66 similar patients with a clinical suspicion of thrombosis but with a normal venogram. All assays were performed without knowledge of the patient's status.Four patients in the deep vein thrombosis-group (7%) had an absent u-PA antigen response upon DDAVP infusion, while a normal response was observed in all control subjects. Patients and controls showed similar increases in t-PA antigen level upon DDAVP. High resting PAI antigen levels were encountered in 5 patients in the deep vein thrombosis-group (9%) and in 6 subjects in the control group (9%).The results from this controlled study indicate that a defective release of u-PA may occur in patients with deep vein thrombosis and may have pathogenetic significance. Furthermore it is concluded that elevation of PAI levels cannot be considered as a specific risk factor for venous thrombosis.

Sign in / Sign up

Export Citation Format

Share Document